Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2020 18:06 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020...
February 28, 2020 18:20 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020...
February 27, 2020 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program

-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
February 26, 2020 16:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
February 19, 2020 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020

CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...
January 31, 2020 18:15 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2020...
January 13, 2020 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C....
January 06, 2020 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
December 31, 2019 18:06 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019,...
December 23, 2019 01:00 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in...